Glutathione reduces the toxicity associated with antitumor therapy of ascites fluid adsorbed over Staphylococcus aureus Cowan I in tumor bearing mice

Toxicology Letters

Volumn 106, Issue 2-3, 1999, Pages 119-127

  Verma, Ashish S ^a   Dwivedi, Premendra D ^a   Mishra, Anil ^a   Ray, Prashanta K ^a  

^a CSIR INDIAN INSTITUTE OF TOXICOLOGY RESEARCH   (India)

Author keywords

Adsorption therapy; Antitumor; Glutathione; Protein A; Staphylococcus aureus Cowan I

Indexed keywords

AMINOPYRINE N DEMETHYLASE; GLUTATHIONE; PROTEIN A; UNSPECIFIC MONOOXYGENASE;

ADSORPTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASCITES FLUID; BIOTRANSFORMATION; CANCER GRAFT; CELL VIABILITY; CONTROLLED STUDY; EHRLICH ASCITES TUMOR; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; STAPHYLOCOCCUS AUREUS; SURVIVAL TIME; TUMOR GROWTH; WEIGHT GAIN;

ADSORPTION; ANILINE HYDROXYLASE; ANIMALS; ANTIGEN-ANTIBODY COMPLEX; CARCINOMA, EHRLICH TUMOR; GLUTATHIONE; MALE; MICE; STAPHYLOCOCCAL PROTEIN A;

ANIMALIA; CANIS FAMILIARIS; FELIS CATUS; MAMMALIA; STAPHYLOCOCCUS AUREUS;

EID: 0032997879     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-4274(98)00387-7     Document Type: Article

References (42)

1. Anderson M.E., Naganuma A., Meister A. Protection against cisplatin toxicity by administration of glutathione and glutathione esters. FASEB J. 4:1990;3251-3255.
2. Bandyopadhyay S.K., Ray P.K. Introduction of bacterial components in post adsorbed plasma during adsorption with Staphylococcus aureus. Cancer. 56:1985;266-272.
3. Benedetti M.S., Louis A., Malnoe A. Prevention of paracetamol induced liver damage in mice with glutathione. J. Pharm. Pharmacol. 27:1975;629-632.
4. Brock N., Stekar J., Phol J., Niemeyer U., Scheffler G. Acrolein, the causative factor of urotoxic side-effect of cyclophosphamide, ifosfamide and trofosfamide and sufosamide. Arzneim. Forch. 29:1979;659-661.
5. Cox P.J., Abel G. Cyclophosphamide cystitis: studies aimed at its minimization. Biochem. Pharmacol. 28:1979;3499-3502.
6. Deneke S.M., Fanburg B.L. Regulation of cellular glutathione. Am. J. Physiol. 257:1989;163-173.
7. DiRe F., Bohm S., Oriana S., Spatti G.B., Zunino F. Efficacy and safety of high dose cisplatin and cyclophosphamide with glutathione protection in treatment of bulky advanced epithelial ovarian cancer. Cancer Chemother. Pharmacol. 25:1990;355-360.
8. Dohadwala M., Ray P.K. In vivo protection by protein A of hepatic microsomal mixed function oxygenase system of cyclophosphamide treated rats. Cancer Chemother. Pharmacol. 14:1985;135-138.
9. Forni, L.G., Willson, R.L. 1983. Vitamin C and consecutive hydrogen atom and electron transfer reactions in free radical protection: a novel catalytic role of glutathione. In: McBrien, D.C.H., Slater T.F. (Eds.), Protective Agents in Cancer. Academic Press, London, pp. 159.
10. Forsgren A., Ghetie V., Lindmark R., Sjoquist J. Protein A and its exploitation. Easmon C.S.F., Adlam C. Staphylococci and Staphylococcal Infections. 1983;429-480 Academic Press, New York.
11. Gaddis T.G., Guthire T.H. Jr., Drew M.J., Sahud M., Howe R.B., Mittleman A. Treatment of plasma refractory thrombotic thrombocytopenic purpura with protein A immunoabsorption. Am. J. Hematol. 55:1997;55-58.
12. Gunn S.A., Gould T.C., Anderson W.A. Mechanism of zinc, cysteine and selenium protection against cadmium induced vascular injury to mouse testis. J. Reprod. Fertil. 15:1968;65-70.
13. Habig W.H., Pabst M.J., Jakoby W.B. Glutathione-S-transferase: the first enzymatic step in mercapturic acid formation. J. Biol. Chem. 249:1974;7130-7139.
14. Hamers F.P., Brakkee J.H., Cavalletti E., Tedeschi M., Marmonti L., Pezzoni G., Neijt J.P., Gispen W.H. Reduced glutathione protects against cisplatin induced nephrotoxicity in rats. Cancer Res. 53:1993;544-549.
15. Hazelton G.A., Hjelle J.J., Klaassen C.D. Effect of cysteine pro-drugs on acetaminophen induced hepatotoxicity. J. Pharmacol. Exp. Ther. 237:1986;341-349.
16. Hook G.E., Bend J.R., Hoel D., Fouts J.R., Gram T.E. Preparation of lung microsomes and comparison of the distribution of enzymes between the subcellular fraction of rabbit lung and liver. J. Pharmacol. Exp. Ther. 182:1972;474-490.
17. Jollow D.J., Mitchell J.R., Zampalione N., Gillette J.R. Bromobenzene induced liver necrosis. Protective role of glutathione and evidence for 3,4-bromobenzene oxide as the hepatotoxic metabolite. Pharmacology. 11:1974;151-169.
18. Kannan R., Kuhlenkamp J.F., Jeandidier E., Trinih H., Ookkhtens M., Kaplowitz N. Evidence for carrier-mediated transport of glutathione across the blood-brain barrier in the rats. J. Clin. Invest. 85:1990;2009-2013.
19. Kiprov D.D., Lippert R., Miller R.G., Sandstrom E., Jones F.R., Cohen R.J., Abrams D., Busch D.F. The use of plasmapheresis, lymphocytapheresis and staph. Protein A immunoadsorption as immunomodulatory therapy in patients with AIDS and AIDS related conditions. J. Clin. Apheresis. 3:1986;133-139.
20. Lauterburg B.H., Mitchell J.R. Toxic doses of acetaminophen suppresses hepatic glutathione synthesis in rats. Hepatology (Baltimore). 2:1982;8-12.
21. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with folin phenol reagent. J. Biol. Chem. 193:1951;265.
22. Mazel P., 1971. In: LaDu, B.N., Mamdel, H.G., Way, E.L. (Eds.), Fundamentals of Drug Metabolism and Drug Disposition. Williams and Wilkins, Baltimore, pp. 527.
23. Messerschmidt G.L., Bowles C., Dean D., Parker M., Lester R., Dowling R., Holohon T., Osborne L., Schaff B.F., McCormack K., Corbitt R., Philip T., Glastein E., Deisseroth A. Phase I trial of Staphylococcus aureus Cowan I immunoperfusion. Cancer Treat. Rep. 66:1981;2027-2031.
24. Mgbodile M.U., Holscher M., Neal R.A. A possible role of reduced glutathione in aflatoxin B1 toxicity: effect of pretreatment of rats with phenobarbital and 3-methylcholanthracene on aflatoxin toxicity. Toxicol. Appl. Pharmacol. 34:1975;128-142.
25. Mills G.C. Glutathione peroxide and the destruction of hydrogen peroxide in animal tissues. Arch. Biochem. Biophys. 86:1960;1-2.
26. Mitchell J.R., Thorgeirsson S.S., Potter W.Z., Jollow D.J., Keiser H. Acetaminophen induced hepatic injury: protective role of glutathione in man and rationale for therapy. Clin. Pharmacol. Ther. 16:1974;676-684.
27. Mizutani T., Nomura H., Yamamoto K., Tajima K. Modification of butylated hydroxytoluene-induced pulmonary toxicity in mice by diethyl maleate, buthionine sulfoxime, and cysteine. Toxicol. Lett. 23:1984;327-333.
28. Ray P.K. Immunosupressor control as a modality of cancer treatment: effect of plasma adsorption with Staphylococcus aureus Protein A. Salinas F.A., Hanna M.G. Jr. Contemporary Topics in Immunobiology. 1985;147-211 Plenum Press, New York.
29. Ray P.K., Cooper D.R., Bessett J.G., Mark R. Antitumor effect of Staphylococcus aureus organism. Fed. Proc. 38:1979;1089.
30. Ray P.K., Besa E., Idiculla A., Rhoads J.E., Bassett J.G., Cooper D.R. Extracorporeal immunoadsorption of myeloma IgG and autoimmune antibodies: a clinically feasible modality of treatment. Clin. Exp. Immunol. 42:1980;308-314.
31. Ray P.K., McLaughlin D., Mohammed J., Idiculla A., Rhoads J.E. Jr., Mark R., Basset J.G., Cooper D.R. Ex vivo immunoadsorption of IgG or its complexes-a new modality of cancer treatment. Serrou B., Rosenfeld C. Immune Complexes and Plasma Exchanges in Cancer Patients. 1981;197-207 Elsevier/North Holland Biomedical Press, Amsterdam.
32. Ray P.K., Raychaudhary S., Allen P. Mechanism of regression of mammary adenocarcinoma in rats following plasma adsorption over Protein A containing Staphylococcus aureus. Cancer Res. 42:1982;4970-4974.
33. Sami S., Takano S., Majima T., Aso H., Nakamura T., Ishida N. Low molecular weight immunosuppressive factors found in elevated amounts in cancer ascites fluid of mice. 1. Isolation, identification and immunosuppressive effects of uric acid and uracil. J. Immunopharmacol. 8:1986;39-58.
34. Snyder H.W. Jr., Mittleman, A., Oral, A., Messerschmidt, G.L., Henry, D.H., Korec, S., Bertram, J.H., Guthrie, T.H. Jr., Ciavarella, D., Wuest, et al., 1993. Treatment of cancer chemotherapy associated thrombotic thrombocytopenic purpura/hemolytic uremia syndrome by Protein A immunoabsorption of plasma. Cancer 71, 1882-1892.
35. 4 administered rats. Biochem. Pharmacol. 36:1987;4055-4058.
36. Takano S., Sami S., Majima T., Ishida N. Low molecular weight immunosuppressive factors found in elevated amount in cancer ascites fluid of mice. 2. 1-Methyladenosine isolated from cancer ascites fluid enhances Listeria infection in mice. J. Immunopharmacol. 8:1986;59-73.
37. Tamura K., Shibata Y., Matsuda Y., Ishida N. Isolation and characterization of an immunosuppressive acidic protein (IAP) from ascites fluid of cancer patients. Cancer Res. 41:1981;3244-3252.
38. Terman D.S., Bertram J.H. Antitumor effects of immobolized Protein A and Staphylococcal products: linkage between toxicity and efficacy and identification of potential tumoricidal reagents. Eur. J. Cancer Clin. Oncol. 21:1985;1115-1122.
39. Verma, A.S., Dwivedi, P.D., Mishra, A., Ray, P.K., 1999. Ehrlich's ascites fluid adsorbed over protein A containing Staphylococcus aureus Cowan I produces inhibition of tumor growth. Immunopharmacol. Immunotoxicol. 21(1) (in press).
40. Vina J., Perez C., Furukawa T., Palacin M., Vina J. Effect of oral glutathione on hepatic glutathione levels in rats and mice. Br. J. Nutr. 62:1989;683-691.
41. Wendel A., Jaeschke H., Gloger M. Drug induced lipid peroxidation in mice II. Protection against paracetamol induced liver necrosis by intravenous liposomally entrapped glutathione. Biochem. Pharmacol. 31:1982;3601-3605.
42. Yamazaki H., Nitta K., Umezawa H. Immunosupression induced with cell free fluid of Ehrlich's carcinoma ascites and its fraction. GANN. 64:1973;83-92.